Open AccessTreatment of Hemodialysis-Associated Adynamic Bone Disease with Teriparatide (PTH<sub>1–34</sub>): A Pilot Study
Author(s) -
Daniel Cejka,
Katharina Kodras,
Till R. Bader,
Martin Haas
Publication year - 2010
Publication title -
kidney and blood pressure research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.806
H-Index - 51
eISSN - 1423-0143
pISSN - 1420-4096
DOI - 10.1159/000316708
Subject(s) - teriparatide , medicine , bone mineral , hemodialysis , femoral neck , parathyroid hormone , osteoporosis , urology , endocrinology , hyperparathyroidism , calcium
Adynamic bone disease (ABD) is caused by a relative or absolute parathyroid hormone (PTH) deficiency. Teriparatide (PTH1-34) is an osteoanabolic agent in clinical use. Here, it was hypothesized that treatment with teriparatide improves bone mineral density (BMD) of ABD patients.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom